$GPLB
Green Planet Bio Engineering Co. Ltd.

2024 Q1 Form 10-K Financial Statement

#000165495424003942 Filed on March 29, 2024

View on sec.gov

Income Statement

Concept 2024 Q1 2023 Q4 2023
Revenue $0.00 $0.00 $0.00
YoY Change
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin $6.470K $13.25K $47.37K
YoY Change -63.73% 73.43% 45.62%
% of Gross Profit
Research & Development
YoY Change
% of Gross Profit
Depreciation & Amortization
YoY Change
% of Gross Profit
Operating Expenses $6.470K $13.25K $47.37K
YoY Change -63.73% 73.43% 45.62%
Operating Profit
YoY Change
Interest Expense -$300.00 $300.00
YoY Change
% of Operating Profit
Other Income/Expense, Net
YoY Change
Pretax Income -$6.470K -$13.55K -$47.67K
YoY Change -63.73% 77.36% 46.53%
Income Tax $0.00 $0.00 $0.00
% Of Pretax Income
Net Earnings -$6.465K -$13.55K -$47.67K
YoY Change -63.76% 77.36% 41.88%
Net Earnings / Revenue
Basic Earnings Per Share
Diluted Earnings Per Share $0.00 $0.00 $0.00
COMMON SHARES
Basic Shares Outstanding 20.01M shares 20.01M shares
Diluted Shares Outstanding

Balance Sheet

Concept 2024 Q1 2023 Q4 2023
SHORT-TERM ASSETS
Cash & Short-Term Investments $0.00 $0.00 $0.00
YoY Change
Cash & Equivalents $0.00 $0.00 $0.00
Short-Term Investments
Other Short-Term Assets
YoY Change
Inventory
Prepaid Expenses
Receivables
Other Receivables
Total Short-Term Assets $0.00 $0.00 $0.00
YoY Change
LONG-TERM ASSETS
Property, Plant & Equipment
YoY Change
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets
YoY Change
Total Long-Term Assets $0.00 $0.00 $0.00
YoY Change
TOTAL ASSETS
Total Short-Term Assets $0.00 $0.00 $0.00
Total Long-Term Assets $0.00 $0.00 $0.00
Total Assets $0.00 $0.00 $0.00
YoY Change
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $3.500K $5.000K $5.000K
YoY Change -40.07%
Accrued Expenses
YoY Change
Deferred Revenue
YoY Change
Short-Term Debt $0.00 $0.00 $0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities $436.1K $429.6K $429.6K
YoY Change 9.08% 12.48% 12.48%
LONG-TERM LIABILITIES
Long-Term Debt $0.00 $0.00 $0.00
YoY Change
Other Long-Term Liabilities
YoY Change
Total Long-Term Liabilities $0.00 $0.00 $0.00
YoY Change
TOTAL LIABILITIES
Total Short-Term Liabilities $436.1K $429.6K $429.6K
Total Long-Term Liabilities $0.00 $0.00 $0.00
Total Liabilities $436.1K $429.6K $429.6K
YoY Change 9.08% 12.48% 12.48%
SHAREHOLDERS EQUITY
Retained Earnings -$1.066M -$1.059M
YoY Change 3.53% 4.71%
Common Stock $20.01K $20.01K
YoY Change 0.0% -96.82%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity -$436.1K -$429.6K -$429.6K
YoY Change
Total Liabilities & Shareholders Equity $0.00 $0.00 $0.00
YoY Change

Cashflow Statement

Concept 2024 Q1 2023 Q4 2023
OPERATING ACTIVITIES
Net Income -$6.465K -$13.55K -$47.67K
YoY Change -63.76% 77.36% 41.88%
Depreciation, Depletion And Amortization
YoY Change
Cash From Operating Activities -$7.965K -$30.67K -$42.67K
YoY Change -33.63% 301.97% 26.19%
INVESTING ACTIVITIES
Capital Expenditures
YoY Change
Acquisitions
YoY Change
Other Investing Activities $0.00
YoY Change
Cash From Investing Activities $0.00 $0.00
YoY Change
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities $7.965K 30.67K $42.67K
YoY Change -33.63% 301.97% 26.19%
NET CHANGE
Cash From Operating Activities -$7.965K -30.67K -$42.67K
Cash From Investing Activities $0.00 $0.00
Cash From Financing Activities $7.965K 30.67K $42.67K
Net Change In Cash $0.00 0.000 $0.00
YoY Change
FREE CASH FLOW
Cash From Operating Activities -$7.965K -$30.67K -$42.67K
Capital Expenditures
Free Cash Flow
YoY Change

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2023Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
10000000 shares
CY2023Q4 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0 shares
CY2023Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2023Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
250000000 shares
CY2023 us-gaap Net Income Loss
NetIncomeLoss
-47670 usd
CY2023 dei Entity Central Index Key
EntityCentralIndexKey
0001392449
CY2023 dei Amendment Flag
AmendmentFlag
false
CY2023 dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
CY2023 dei Entity Emerging Growth Company
EntityEmergingGrowthCompany
false
CY2023 dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
FY
CY2023 dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2023
CY2023 dei Document Fin Stmt Error Correction Flag
DocumentFinStmtErrorCorrectionFlag
false
CY2022Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.001
CY2022Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
10000000 shares
CY2022Q4 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0 shares
CY2022Q4 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0 shares
CY2023Q4 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0 shares
CY2022Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2022Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
250000000 shares
CY2022Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
20006402 shares
CY2022Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
20006402 shares
CY2023Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
20006402 shares
CY2023 dei Document Type
DocumentType
10-K
CY2023 dei Document Annual Report
DocumentAnnualReport
true
CY2023 dei Document Period End Date
DocumentPeriodEndDate
2023-12-31
CY2023 dei Document Transition Report
DocumentTransitionReport
false
CY2023 dei Entity File Number
EntityFileNumber
000-52622
CY2023 dei Entity Registrant Name
EntityRegistrantName
GREEN PLANET BIOENGINEERING CO., LTD.
CY2023 dei Entity Incorporation State Country Code
EntityIncorporationStateCountryCode
DE
CY2023 dei Entity Tax Identification Number
EntityTaxIdentificationNumber
37-1532842
CY2023 dei Entity Address Address Line1
EntityAddressAddressLine1
20807 Biscayne Blvd.
CY2023 dei Entity Address Address Line2
EntityAddressAddressLine2
Suite 203
CY2023 dei Entity Address City Or Town
EntityAddressCityOrTown
Aventura
CY2023 dei Entity Address State Or Province
EntityAddressStateOrProvince
FL
CY2023 dei Entity Address Postal Zip Code
EntityAddressPostalZipCode
33180
CY2023 dei City Area Code
CityAreaCode
786
CY2023 dei Local Phone Number
LocalPhoneNumber
279-2900
CY2023 dei Entity Well Known Seasoned Issuer
EntityWellKnownSeasonedIssuer
No
CY2023 dei Entity Voluntary Filers
EntityVoluntaryFilers
No
CY2023 dei Entity Current Reporting Status
EntityCurrentReportingStatus
Yes
CY2023 dei Entity Interactive Data Current
EntityInteractiveDataCurrent
Yes
CY2023 dei Entity Filer Category
EntityFilerCategory
Non-accelerated Filer
CY2023 dei Entity Small Business
EntitySmallBusiness
true
CY2023 dei Entity Shell Company
EntityShellCompany
true
CY2023Q2 dei Entity Public Float
EntityPublicFloat
722205 usd
CY2024Q1 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
20006402 shares
CY2023 dei Auditor Firm
AuditorFirmId
5036
CY2023 dei Auditor Name
AuditorName
Assurance Dimensions
CY2023 dei Auditor Location
AuditorLocation
Margate, Florida
CY2023Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
0 usd
CY2022Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
0 usd
CY2023Q4 us-gaap Assets Current
AssetsCurrent
0 usd
CY2022Q4 us-gaap Assets Current
AssetsCurrent
0 usd
CY2023Q4 us-gaap Accounts Payable And Accrued Liabilities Current
AccountsPayableAndAccruedLiabilitiesCurrent
5000 usd
CY2022Q4 us-gaap Accounts Payable And Accrued Liabilities Current
AccountsPayableAndAccruedLiabilitiesCurrent
0 usd
CY2023Q4 us-gaap Other Liabilities Current
OtherLiabilitiesCurrent
424590 usd
CY2022Q4 us-gaap Other Liabilities Current
OtherLiabilitiesCurrent
381920 usd
CY2023Q4 us-gaap Liabilities Current
LiabilitiesCurrent
429590 usd
CY2022Q4 us-gaap Liabilities Current
LiabilitiesCurrent
381920 usd
CY2023Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.001
CY2023Q4 us-gaap Preferred Stock Value
PreferredStockValue
0 usd
CY2022Q4 us-gaap Preferred Stock Value
PreferredStockValue
0 usd
CY2023Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
20006402 shares
CY2023Q4 us-gaap Common Stock Value
CommonStockValue
20006 usd
CY2022Q4 us-gaap Common Stock Value
CommonStockValue
20006 usd
CY2023Q4 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
609614 usd
CY2022Q4 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
609614 usd
CY2023Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-1059210 usd
CY2022Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-1011540 usd
CY2023Q4 us-gaap Stockholders Equity
StockholdersEquity
-429590 usd
CY2022Q4 us-gaap Stockholders Equity
StockholdersEquity
-381920 usd
CY2023Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
0 usd
CY2022Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
0 usd
CY2023 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
47370 usd
CY2022 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
32533 usd
CY2023 us-gaap Interest Expense
InterestExpense
300 usd
CY2022 us-gaap Interest Expense
InterestExpense
0 usd
CY2023 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-47670 usd
CY2022 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-32533 usd
CY2023 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
0 usd
CY2022 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
0 usd
CY2023 us-gaap Net Income Loss
NetIncomeLoss
-47670 usd
CY2022 us-gaap Net Income Loss
NetIncomeLoss
-32533 usd
CY2023 gplb Basic And Diluted Weighted Average Number Of Share Outstanding
BasicAndDilutedWeightedAverageNumberOfShareOutstanding
20006402 shares
CY2022 gplb Basic And Diluted Weighted Average Number Of Share Outstanding
BasicAndDilutedWeightedAverageNumberOfShareOutstanding
20006402 shares
CY2023 us-gaap Profit Loss
ProfitLoss
47670 usd
CY2022 us-gaap Profit Loss
ProfitLoss
32533 usd
CY2023 us-gaap Increase Decrease In Accounts Payable And Accrued Liabilities
IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
5000 usd
CY2022 us-gaap Increase Decrease In Accounts Payable And Accrued Liabilities
IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
0 usd
CY2023 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-42670 usd
CY2022 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-32533 usd
CY2023 us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
0 usd
CY2022 us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
0 usd
CY2023 us-gaap Proceeds From Related Party Debt
ProceedsFromRelatedPartyDebt
42670 usd
CY2022 us-gaap Proceeds From Related Party Debt
ProceedsFromRelatedPartyDebt
32533 usd
CY2023 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
42670 usd
CY2022 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
32533 usd
CY2023 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Excluding Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect
0 usd
CY2022 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Excluding Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect
0 usd
CY2022Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
0 usd
CY2021Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
0 usd
CY2023Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
0 usd
CY2022Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
0 usd
CY2023 us-gaap Interest Paid Net
InterestPaidNet
300 usd
CY2022 us-gaap Interest Paid Net
InterestPaidNet
0 usd
CY2023 us-gaap Income Taxes Paid
IncomeTaxesPaid
0 usd
CY2022 us-gaap Income Taxes Paid
IncomeTaxesPaid
0 usd
CY2021Q4 us-gaap Stockholders Equity
StockholdersEquity
-349387 usd
CY2022 us-gaap Net Income Loss
NetIncomeLoss
-32533 usd
CY2022Q4 us-gaap Stockholders Equity
StockholdersEquity
-381920 usd
CY2023 us-gaap Net Income Loss
NetIncomeLoss
-47670 usd
CY2023Q4 us-gaap Stockholders Equity
StockholdersEquity
-429590 usd
CY2023 us-gaap Use Of Estimates
UseOfEstimates
<p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">The preparation of financial statements in accordance with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and the disclosure of contingent assets and liabilities as of the date of the financial statements and the reported amounts of revenue and expenses for the years reported.  Actual results could differ from those estimates.  Significant items that require estimates were accruals of liabilities.</p>
CY2023Q4 gplb Due To Related Party Current
DueToRelatedPartyCurrent
424590 usd
CY2022Q4 gplb Due To Related Party Current
DueToRelatedPartyCurrent
381920 usd
CY2023Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
10000000 shares
CY2023Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.001
CY2023 gplb Voting Rights Shares
VotingRightsShares
1000 shares
CY2023Q4 us-gaap Convertible Preferred Stock Shares Issued Upon Conversion
ConvertiblePreferredStockSharesIssuedUponConversion
1000 shares
CY2023Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
250000000 shares
CY2023Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2023Q4 us-gaap Operating Loss Carryforwards
OperatingLossCarryforwards
1023500 usd
CY2023 gplb Description Of Aseet And Allowances
DescriptionOfAseetAndAllowances
The valuation allowance decreased by approximately $1,000 to reflect state tax rate of 5.5%
CY2023 us-gaap Income Tax Reconciliation Income Tax Expense Benefit At Federal Statutory Income Tax Rate
IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate
-12394 usd
CY2022 us-gaap Income Tax Reconciliation Income Tax Expense Benefit At Federal Statutory Income Tax Rate
IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate
-8450 usd
CY2023 us-gaap Income Tax Reconciliation Change In Enacted Tax Rate
IncomeTaxReconciliationChangeInEnactedTaxRate
0 usd
CY2022 us-gaap Income Tax Reconciliation Change In Enacted Tax Rate
IncomeTaxReconciliationChangeInEnactedTaxRate
0 usd
CY2023 us-gaap Income Tax Reconciliation Change In Deferred Tax Assets Valuation Allowance
IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance
12394 usd
CY2022 us-gaap Income Tax Reconciliation Change In Deferred Tax Assets Valuation Allowance
IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance
8450 usd
CY2023 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
0 usd
CY2022 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
0 usd
CY2023 gplb Cumulative Tax Effect Rate
CumulativeTaxEffectRate
0.21 pure
CY2022 gplb Cumulative Tax Effect Rate
CumulativeTaxEffectRate
0.21 pure
CY2023Q4 us-gaap Deferred Tax Assets Operating Loss Carryforwards
DeferredTaxAssetsOperatingLossCarryforwards
258844 usd
CY2022Q4 us-gaap Deferred Tax Assets Operating Loss Carryforwards
DeferredTaxAssetsOperatingLossCarryforwards
246450 usd
CY2023Q4 us-gaap Deferred Tax Assets Valuation Allowance
DeferredTaxAssetsValuationAllowance
258844 usd
CY2022Q4 us-gaap Deferred Tax Assets Valuation Allowance
DeferredTaxAssetsValuationAllowance
246450 usd
CY2023Q4 us-gaap Deferred Tax Assets Net
DeferredTaxAssetsNet
0 usd
CY2022Q4 us-gaap Deferred Tax Assets Net
DeferredTaxAssetsNet
0 usd
CY2011Q4 us-gaap Operating Loss Carryforwards
OperatingLossCarryforwards
213844 usd

Files In Submission

Name View Source Status
0001654954-24-003942-index-headers.html Edgar Link pending
0001654954-24-003942-index.html Edgar Link pending
0001654954-24-003942.txt Edgar Link pending
0001654954-24-003942-xbrl.zip Edgar Link pending
Financial_Report.xlsx Edgar Link pending
gplb-20231231.xsd Edgar Link pending
gplb_10k.htm Edgar Link pending
FilingSummary.xml Edgar Link unprocessable
gplb-20231231_cal.xml Edgar Link unprocessable
gplb-20231231_def.xml Edgar Link unprocessable
gplb-20231231_lab.xml Edgar Link unprocessable
gplb-20231231_pre.xml Edgar Link unprocessable
gplb_10kimg7.jpg Edgar Link pending
gplb_ex311.htm Edgar Link pending
gplb_ex312.htm Edgar Link pending
gplb_ex32.htm Edgar Link pending
MetaLinks.json Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R3.htm Edgar Link pending
R4.htm Edgar Link pending
R5.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending
gplb_10k_htm.xml Edgar Link completed